SCHEMBL2961683

SCHEMBL2961683

Cc1ccc(-c2nc3c(C(=O)O)cc(Cl)cc3o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 6/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
HPGD P15428 4/20 0.51
NFKB1 P19838 3/20 0.51
NFKB2 Q00653 3/20 0.51
RELA Q04206 3/20 0.51
LMNA P02545 2/20 0.51
DHODH Q02127 2/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
HSD17B10 Q99714 4/20 0.46
TP53 P04637 3/20 0.46
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 4/20 0.44
ATM Q13315 1/20 0.44
MAOA P21397 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959750 0.87 DHODH (0.51) ALDH1A1KDM4ESMN1; SMN2DHODHNPC1
SCHEMBL2953614 0.86 MAPT (0.50) ALDH1A1KDM4ESMN1; SMN2HPGDLMNA
SCHEMBL2964683 0.85 MAPT (0.47) ALDH1A1KDM4ESMN1; SMN2HPGDNFKB1
SCHEMBL2963895 0.79 NPC1 (0.41) ALDH1A1KDM4ESMN1; SMN2LMNADHODH
SCHEMBL2960023 0.79 IKBKB (0.44) ALDH1A1KDM4EDHODHNPSR1MAPT
SCHEMBL206232 0.79 TOP2A (0.56) ALDH1A1KDM4ESMN1; SMN2HPGDNFKB1
SCHEMBL2963283 0.77 KMT2A (0.40) ALDH1A1KDM4EHPGDDHODHNPC1
SCHEMBL1004448 0.76 AKR1C4 (0.42) ALDH1A1KDM4EHPGDDHODHNPC1
SCHEMBL2951056 0.75 HTR3A (0.69) ALDH1A1TSHRPDE4D
SCHEMBL5243252 0.74 HTR3A (0.46) ALDH1A1KDM4ESMN1; SMN2HPGDNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781430-B2 Benzoxazole carboxamides for treating CINV and IBS-D ALBANY MOLECULAR RESEARCH, INC. (US) 2010-08-24 US disclosed
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2008-05-08 US disclosed
CN-101160307-A Benzoxazole carboxamides for the treatment of CINV and IBS-D AMR TECHNOLOGY INC (US) 2008-04-09 CN disclosed
US-7307094-B2 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2007-12-11 US disclosed
EP-1853597-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR Technology, Inc. (US) 2007-11-14 EP disclosed
WO-2006089100-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-24 WO disclosed
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D HTR3E, BRS3, HTR3A ALDH1A1 3208/4885KDM4E 3917/4885SMN1; SMN2 4403/4885
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D HTR3E, BRS3, HTR3A ALDH1A1 3208/4885KDM4E 3917/4885SMN1; SMN2 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.